黄素在缓解人类疾病中的动态作用:治疗应用的最新进展
Md Shamshir Alam1, Md Jamir Anwar2, Manish Kumar Maity3
1Department of Pharmacy Practice, College of Pharmacy, National University of Science and Technology, P.O. Box 620, Bosher, Muscat 130, Oman.
Pharmaceuticals (Basel, Switzerland)
|January 8, 2025
概括
黄 (Curcuma longa) 中的活性化合物黄,由于其抗氧化特性,显示出治疗慢性炎症疾病和相关疾病的前景. 虽然通常是安全的,但其抗凝效应需要在治疗应用中仔细考虑.
科学领域:
- 药理学和植物化学
- 综合医学是一个整体的医学.
- 分子生物学分子生物学
背景情况:
- 像黄 (Curcuma longa) 这样的草药在全球范围内被广泛使用,特别是在发展中国家,因为它们的负担能力和安全性.
- 黄在亚洲传统上用于治疗各种疾病,包括炎症和感染,具有悠久的历史.
- 黄中主要的生物活性化合物黄因其治疗潜力而得到认可.
研究的目的:
- 审查黄素作用的分子机制.
- 评估黄素在各种人类疾病中的疗效.
- 探索黄素在预防和治疗慢性炎症和相关疾病中的作用.
主要方法:
- 综合了最近的生物化学和临床研究研究.
- 对黄素准的分子通路的分析.
- 对各种健康状况的人类临床试验数据的评估.
主要成果:
- 黄素表现出强大的抗氧化特性,对于对抗慢性炎症至关重要.
- 有证据表明,在癌症,炎症性肠道疾病,关节炎和神经系统疾病等疾病中具有有效性.
- 黄素显示出良好的安全性,尽管抗凝效应需要谨慎.
结论:
- 黄素的抗氧化和抗炎作用将其定位为一种有价值的治疗剂.
- 进一步的研究可以阐明其在治疗慢性疾病和改善患者治疗结果方面的全部潜力.
- 黄素是现代治疗应用的有希望的天然化合物,需要继续进行研究.
相关概念视频
Microorganisms in Medicine and Therapeutics
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Inflammatory Bowel Disease IV: Pharmacological Management
110
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
110
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
141
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
141
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
114
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
114
Clinical Trials: Overview
2.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
2.7K


